Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential by Shankar, Sharmila et al.
BioMed  Central
Page 1 of 17
(page number not for citation purposes)
Journal of Molecular Signaling
Open Access Research article
Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 
tri-hydroxystilbene): molecular mechanisms and therapeutic 
potential
Sharmila Shankar, Qinghe Chen, Imtiaz Siddiqui, Krishna Sarva and 
Rakesh K Srivastava*
Address: Department of Biochemistry, University of Texas Health Science Center at Tyler, Tyler, Texas, USA 75703
Email: Sharmila Shankar - sharmila.shankar@uthct.edu; Qinghe Chen - qinghe.chen@uthct.edu; Imtiaz Siddiqui - imtiaz.siddiqui@uthct.edu; 
Krishna Sarva - krishna.sarva@uthct.edu; Rakesh K Srivastava* - rakeh.srivastava@uthct.edu
* Corresponding author    
Abstract
Background: We have previously shown that prostate cancer LNCaP cells are resistant to TRAIL,
and downregulation of PI-3K/Akt pathway by molecular and pharmacological means sensitizes cells
to undergo apoptosis by TRAIL and curcumin. The purpose of this study was to examine the
molecular mechanisms by which resveratrol sensitized TRAIL-resistant LNCaP cells.
Results: Resveratrol inhibited growth and induced apoptosis in androgen-dependent LNCaP cells,
but had no effect on normal human prostate epithelial cells. Resveratrol upregulated the expression
of Bax, Bak, PUMA, Noxa, Bim, TRAIL-R1/DR4 and TRAIL-R2/DR5, and downregulated the
expression of Bcl-2, Bcl-XL, survivin and XIAP. Treatment of LNCaP cells with resveratrol resulted
in generation of reactive oxygen species, translocation of Bax and p53 to mitochondria, subsequent
drop in mitochondrial membrane potential, release of mitochondrial proteins (cytochrome c, AIF,
Smac/DIABLO and Omi/HtrA2), activation of caspase-3 and caspase-9 and induction of apoptosis.
The ability of resveratrol to sensitize TRAIL-resistant LNCaP cells was inhibited by dominant
negative FADD, caspase-8 siRNA or N-acetyl cysteine. Smac siRNA inhibited resveratrol-induced
apoptosis, whereas Smac N7 peptide induced apoptosis and enhanced the effectiveness of
resveratrol.
Conclusion: Resveratrol either alone or in combination with TRAIL or Smac can be used for the
prevention and/or treatment of human prostate cancer.
Background
Prostate cancer is the most frequently diagnosed male
cancer and the second leading cause of cancer-related
mortality in men in the Western world. In 2005, there
were 232,090 new cases of prostate cancer diagnosed in
the United States and 30,350 cancer deaths [1]. The
molecular mechanisms responsible for the initiation and
progression of prostate cancer have not been elucidated,
and the only established risk factors for this disease
include age, ethnic group, and family history [2]. In addi-
tion, the importance of diet in prostate carcinogenesis has
been sown by epidemiological studies of Asian immi-
grants to Hawaii or California [3]. One of the most prom-
ising dietary compounds implicated in the
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chemoprevention of prostate cancer is resveratrol, a con-
stituent of red wine and grapes [4-6].
Epidemiological and preclinical evidence suggests that
polyphenolic phytochemicals possess cancer chemopre-
ventive properties [4]. There is mounting evidence in the
literature that resveratrol is a promising natural com-
pound for prevention and treatment of a variety of human
cancers [4-6]. Resveratrol (3,4',5 tri-hydroxystilbene) has
been shown to possess a protective effect in prostate can-
cer in various pre-clinical animal models and has been
reported to be effective in several other cancer types as
well [7-10]. Numerous studies have reported interesting
properties of resveratrol as a preventive agent against
important pathologies i.e. vascular diseases, cancers, viral
infection or neurodegenerative processes. Resveratrol acts
on the process of carcinogenesis by affecting tumor initia-
tion, promotion and progression, and suppresses the final
steps of carcinogenesis, i.e. angiogenesis and metastasis. It
induces apoptosis, and cell cycle arrest, and modulates
several signal transduction pathways. Interestingly, resver-
atrol does not appear to be toxic in animal models. Fur-
thermore, resveratrol has been shown to sensitize cancer
cells to chemotherapy and radiotherapy. Despite consid-
erable progress towards our understanding of the signal-
ing pathways leading to resveratrol-mediated apoptosis,
the molecular mechanisms by which resveratrol sensitizes
prostate cancer cells to TRAIL treatment is not fully under-
stood.
The tumor suppressor p53 protein plays a major role in
cell cycle arrest, DNA repair and apoptosis [11]. It regu-
lates apoptosis through both transcriptional-dependent
and in-dependent mechanisms. Through transcription-
dependent pathways, p53 functions as a transactivator to
up-regulate downstream proapoptotic genes (e.g. Bax,
Noxa, and PUMA), and functions as a repressor to down-
regulate antiapoptotic genes (e.g. Bcl-2) promoting apop-
tosis. Bax induces apoptosis by enhancing the release of
mitochondrial proteins (e.g. cytochrome c and Smac/DIA-
BLO) to cytosol. Through transcription-independent
pathways, p53 has a direct apoptogenic role where it
translocates to mitochondria in response to cellular stress,
resulting in apoptosis via interaction with antiapoptotic
Bcl-2 and Bcl-XL proteins that alter the mitochondrial
membrane potential and induce cytochrome c and Smac/
DIABLO release into the cytosol with resultant caspase
activation [12,13]. The elucidation of the p53-dependent
pathway, resulting in mitochondrial outer membrane per-
meabilization through the pro-apoptotic Bcl-2 family pro-
teins, is a key to unveiling the mechanism of stress-
induced apoptosis. It is not know whether resveratrol reg-
ulates p53 functions via transcriptional independent
mechanisms.
TRAIL (TNF-related apoptosis-inducing ligand) induces
apoptosis in a wide variety of transformed cells [14-16]. It
binds to several distinct receptors: (a) TRAIL-R1 (DR4)
[17]; (b) TRAIL-R2 (DR5) [18]; (c) TRAIL-R3 (DcR1) [19];
and (d) TRAIL-R4 (DcR2) [20]. DR4 and DR5 contain the
intracellular death domain (DD) which is essential for
binding with an adaptor protein Fas-associated death
domain (FADD) and the formation of active death-induc-
ing signaling complex (DISC) [21,22]. In contrast, neither
DcR1 nor DcR2 induce apoptosis due to a complete or
partial lack of the intracellular DD, respectively [23,24].
TRAIL receptors are expressed in cancer cells but their
expression may not be sufficient to induce apoptosis. The
binding of TRAIL to DR4 and DR5 leads to the activation
of caspase-8 or caspase-10 after recruitment of FADD
[25,26], that in turn activates downstream effector cas-
pases such as caspase-3, and caspase-7 [16]. Activation of
caspase-8 or caspase-10 also cleaves BID (a Bcl-2 inhibi-
tory protein) [27] to truncated BID (tBID), which triggers
mitochondrial depolarization and causes subsequent
release of mitochondrial proteins to cytosol [16,28-30].
Antiapoptotic Bcl-2 and Bcl-XL proteins preserve mito-
chondrial transmembrane potential and blocks the
release of mitochondrial proteins such as cytochrome c,
whereas Bax and Bak has opposite effect [31-33]. The cyto-
chrome c binds to apaf-1 (apoptotic protease-activating
factor 1) and, in the presence of dATP, recruits and acti-
vates procaspase-9 to form the apoptosome [30,34].
Inhibitor of apoptosis proteins (IAPs) interact with and
inhibit caspase-3, caspase-7 and caspase-9. Finally, the
activation of caspases causes cleavage of several substrates
leading to apoptosis [30,34].
We and others have shown that TRAIL-resistant cancer cell
lines can be sensitized by RNA synthesis inhibitors
[35,36], protein synthesis inhibitors [35-37], chemother-
apeutic agents [38-40], histone deacetylase inhibitors [41]
or ionizing radiation [42,43]. Furthermore, we have
recently demonstrated that downregulation of Akt/PKB or
NFκB sensitized breast, prostate and lung cancer cells to
TRAIL in vitro [36,37,44]. Study of the intracellular mech-
anisms that control TRAIL sensitivity may enhance our
knowledge of death receptor-mediated signaling and help
to develop resveratrol and/or TRAIL-based approaches to
cancer prevention/treatment. Such information will not
only allow rational design of resveratrol- and TRAIL-based
strategies for prevention and/or treatment of prostate can-
cers but could also facilitate development of mechanism-
driven combination protocols for optimal clinical effects.
Elucidation of the mechanism(s) for anti-proliferative
activity of resveratrol and TRAIL is an important step in a
process aimed at ultimately applying this knowledge to
clinical trials in humans. Prior to clinical trials, however,
it is essential that the molecular mechanisms by whichJournal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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resveratrol sensitizes TRAIL-resistant cells are fully under-
stood.
The objectives of our study were to examine the molecular
mechanisms by which resveratrol sensitized TRAIL-resist-
ant prostate cancer LNCaP cells. Here, we demonstrated
that resveratrol inhibited cell growth, induced apoptosis
and sensitized TRAIL-resistant LNCaP cells through multi-
ple mechanisms. Resveratrol induced apoptosis through
generating reactive oxygen species, targeting p53 to mito-
chondria, regulating Bcl-2 family members, death recep-
tors DR4 and DR5) and IAPs, and releasing apoptogenic
mitochondrial proteins (cytochrome c, Smac/DIABLO,
and Omi/Htr2). Thus, resveratrol can be used either alone
or in combination with TRAIL to prevent and/or treat
human prostate cancer.
Results
Resveratrol sensitizes TRAIL-resistant prostate cancer 
LNCaP cells
We have previously shown that TRAIL induces apoptosis
in prostate cancer cells with varying sensitivity, and
LNCaP cells are resistant to TRAIL [36]. We first measured
the effects of resveratrol and/or TRAIL on cell viability of
LNCaP cells expressing wild type p53 (Fig. 1A). Resvera-
trol (10–30 µM) inhibited cell viability in LNCaP cells in
a dose-dependent manner (Fig. 1A). By comparison,
TRAIL had no effects in LNCaP cells. Interestingly, resver-
atrol sensitized TRAIL-resistant LNCaP cells. We next
examined whether resveratrol and/or TRAIL had any effect
on human normal prostate epithelial cells (PrEC) (Fig.
1B). Resveratrol in the presence or absence of TRAIL had
no effect on apoptosis in human normal prostate epithe-
lial cells.
Since anchorage independent growth is one of the charac-
teristics of tumor formation, we sought to measure the
effects of resveratrol and TRAIL on colony formation in
soft agar (Fig. 1C). Resveratrol inhibited colony growth of
LNCaP cells in a dose-dependent manner. By comparison,
TRAIL had no effects on colonies formed by LNCaP cells.
Resveratrol sensitized LNCaP colonies to TRAIL treat-
ment. These data demonstrate that resveratrol inhibits
anchorage-dependent and independent growth of pros-
tate cancer cells, and enhances the therapeutic potential of
TRAIL.
The sequence of drug administration is important to
obtain maximum therapeutic benefits in combination
therapy. The pretreatment of cells with resveratrol may
increase the apoptotic effects of TRAIL by up-regulating
death receptors. We therefore examined whether pretreat-
ment of LNCaP cells with resveratrol followed by TRAIL
induced more apoptosis than the concurrent treatment or
TRAIL followed by resveratrol (Fig. 1D). LNCaP cells were
pretreated with resveratrol for 24 h, followed by TRAIL for
another 24 h, and vice versa. Interestingly, the pretreat-
ment of cells with resveratrol followed by TRAIL induced
more apoptosis than concurrent treatment or single agent
alone. In order to understand this synergistic interaction,
reverse sequence of drug exposure was used in which cells
were pretreated with TRAIL for 24 h followed by treatment
with resveratrol for additional 24 h. Reverse sequence of
treatment, TRAIL followed by resveratrol, has resulted sig-
nificantly less apoptosis than the sequential treatment of
cells with resveratrol followed by TRAIL. However, there
was no difference between concurrent treatment and
TRAIL followed by resveratrol. These data suggest that
sequential treatment of cells with resveratrol followed by
TRAIL can be used to enhance the apoptosis inducing
potential of TRAIL.
Resveratrol upregulates TRAIL-R1/DR4 and TRAIL-R2/
DR5 receptors
We and others have shown that TRAIL induces apoptosis
by binding to TRAIL-R1/DR4 and TRAIL-R2/DR5 [25,26].
Upregulation of death receptor on the cell-surface may
either enhance the biological activity of TRAIL in sensitive
cells or sensitize TRAIL-resistant cells. Since resveratrol
enhances the apoptosis-inducing potential of TRAIL, we
sought to examine the effects of resveratrol on death
receptor expressions in LNCaP cells. Resveratrol induced
expression of death receptors TRAIL-R1/DR4 and TRAIL-
R2/DR5 in LNCaP cells (Fig. 2A and 2B). In contrast, it has
no effect on the expression of decoy receptors DcR1 and
DcR2 (Fig. 2C and 2D). These data suggest that upregula-
tion of death receptors DR4 and/or DR5 may be one of the
mechanisms by which resveratrol sensitizes prostate can-
cer cells to TRAIL.
Resveratrol sensitizes TRAIL-resistant LNCaP cells through 
activation of caspases and cleavage of Poly-ADP Ribose 
Polymerase (PARP)
Caspase activation plays an important role in apoptosis
triggered by stress stimuli. We therefore examined the acti-
vation of caspase-3 and caspase-8 by fluorogenic assay
and Western blot analysis in LNCaP cells (Fig. 3A–C). Res-
veratrol induced caspase-3 activity in LNCaP cells in a
dose-dependent manner (Fig. 3A). TRAIL had no effects
on caspase-3 activity (Fig. 3A and 3B). Resveratrol and
TRAIL alone had no significant effect on caspase-8 activa-
tion (Fig. 3B). However, the combination of resveratrol
and TRAIL enhanced caspase-3 and caspase-8 activities.
Poly-ADP Ribose Polymerase (PARP) is one of the caspase
substrates which is cleaved by caspase(s) [25,41-43]. We
therefore examined the cleavage of pro-caspase-3, pro-cas-
pase-8, pro-caspase-9, and PARP in LNCaP cells by the
Western blot analysis (Fig. 3C). Caspase-8 antibody recog-
nizes the whole molecule, whereas caspase-9, caspase-3Journal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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and PARP antibodies recognize their cleavage products.
Treatment of LNCaP cells with resveratrol resulted in
cleavage of pro-caspase-3, and pro-caspases-9, but has
effect on cleavage of pro-caspase-8. TRAIL alone had no
effect on the cleavage of pro-caspase-8, pro-caspase-3,
pro-caspase-9 and PARP compared to untreated control.
Interestingly, the combination of resveratrol and TRAIL
significantly cleaved pro-caspase-8, pro-caspase-9, pro-
caspase-3 and PARP.
Resveratrol regulates expression of Bcl-2 family members 
and inhibitors of apoptosis proteins (IAPs)
Bcl-2 family members are important regulator of apopto-
sis, and overexpression of Bcl-2 and Bcl-XL may confer
Interactive effects of resveratrol and TRAIL on cell viability, colony formation and apoptosis in prostate cancer cells Figure 1
Interactive effects of resveratrol and TRAIL on cell viability, colony formation and apoptosis in prostate cancer cells. (A), 
Effects of resveratrol and/or TRAIL on cell viability in LNCaP cells. Cells were treated with various doses of resveratrol (0–30 
µM) in the presence or absence of TRAIL (50 nM) for 48 h. Cell viability was measured by XTT assay as described in materials 
and methods. Data represent mean ± SD. * = Significantly different from respective control, P < 0.05. (B), Effects of resveratrol 
and/or TRAIL on apoptosis in human normal prostate epithelial cells (PrEC). PrEC were treated with resveratrol (20 µM) in 
the presence or absence of TRAIL (50 nM) for 48 h, and apoptosis was measured by TUNEL assay. (C), Effects of resveratrol 
and/or TRAIL on colony formation by LNCaP cells. Cells were treated with various doses of resveratrol (0–30 µM) in the 
presence or absence of TRAIL (50 nM). After three weeks, no of colonies were stained and counted. Data represent mean ± 
SD. * = Significantly different from respective control, P < 0.05. (D), Effects of different treatment combinations of resveratrol 
and TRAIL on apoptosis. LNCaP cells were treated with resveratrol (20 µM) in the presence or absence of TRAIL (50 nM). 
TRAIL was added simultaneously with resveratrol (cotreatment), before or after 24 h of resveratrol treatment. Apoptosis was 
measured by TUNEL assay. Data represent mean ± SD. * = Significantly different from respective control, P < 0.05.Journal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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resistance to chemotherapy [31,32]. They regulate mito-
chondrial outer membrane integrity, cytochrome c
release, caspase activation and apoptosis [45-47]. Some of
the proteins within this family, including Bcl-2 and Bcl-XL
inhibit apoptosis, and others, such as Bax, Bak, Noxa and
Bim promote apoptosis. We therefore sought to examine
the effects of resveratrol on Bcl-2 family members in
LNCaP cells (Fig. 4A and 4B). Resveratrol induced expres-
sion of proapoptotic proteins Noxa, Bim, Bak, Bak and
Bid, and inhibited antiapoptotic proteins Bcl-2 and Bcl-
XL. These data suggest that resveratrol regulates both pro-
and anti-apoptotic members of Bcl-2 family.
Inhibitors of apoptosis proteins (IAPS) have been shown
to neutralize the activity of caspases [48]. We therefore
examined the effects of resveratrol on the expression of
XIAP, survivin, cIAP1 and cIAP2 (Fig. 4C). None of the
doses of resveratrol inhibited the expression of IAPs at 24
h. However, resveratrol inhibited the expression of XIAP
and survivin at 48 h. There was no effect of resveratrol on
cIAP1 and cIAP2 at 48 h. These data suggest that inhibi-
tion of XIAP and survivin by resveratrol may sequester less
caspase(s) and thus enhance apoptosis induction by res-
veratrol.
Resveratrol dysrupts mitochondrial homeostasis and 
causes the release of mitochondrial proteins
During apoptosis, engagement of the mitochondrial path-
way involves the permeabilization of the outer mitochon-
drial membrane (OMM), which leads to the release of
cytochrome c and other apoptogenic proteins [49,50].
OMM permeabilization depends on activation, transloca-
tion and oligomerization of multidomain Bcl-2 family
proteins such as Bax. We therefore measured mitochon-
Effects of resveratrol on the surface expression of death receptors Figure 2
Effects of resveratrol on the surface expression of death receptors. (A, B, C and D), LNCaP cells were treated with resveratrol 
(0, or 10 µM) for 48 h and expressions of death receptors TRAIL-R1/DR4, TRAIL-R2/DR5, TRAIL-R3/DcR1 and TRAIL-R4/
DcR2 were measured by flowcytometry.Journal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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drial membrane potential (∆ψm), and release of cyto-
chrome c, AIF, Smac/DIABLO, and Omi/HtrA2 from
mitochondria to cytosol. Treatment of prostate cancer
LNCaP cells with resveratrol resulted in a drop off ∆ψm
over time (Fig. 5A). Since resveratrol sensitized TRAIL-
resistant cells to undergo apoptosis, we next examined the
interactive effects of resveratrol and TRAIL on ∆ψm (Fig.
5B). Resveratrol and TRAIL alone or in combination with
each other had no effect on ∆ψm up to 2 h. Although
TRAIL was ineffective alone, the treatment of LNCaP cells
with resveratrol caused a drop in ∆ψm at 8 h and 16 h.
Interestingly, the combination of resveratrol and TRAIL
resulted in significant drop in ∆ψm at both time points.
We next examined the effects of resveratrol on the release
of cytochrome c and Smac/DIABLO from mitochondria to
cytosol by immunocytochemistry (Fig. 6A). In control
cells, cytochrome c and Smac were predominantly in
mitochondria as evident by yellow color mitochondria
(colocalization of green color cyto c or Smac in red color
mitochondria). Treatment of LNCaP cells with resveratrol
resulted in the release of cytochrome c and Smac from
Interactive effects of resveratrol and TRAIL on caspase activation and PARP cleavage Figure 3
Interactive effects of resveratrol and TRAIL on caspase activation and PARP cleavage. (A), Effects of resveratrol and/or TRAIL 
on caspase-3 activity in LNCaP cells. Cells were treated with resveratrol (0–30 µM) in the presence or absence of TRAIL (50 
nM) for 24 h. At the end of incubation period, caspase-3 activity was measured by flurometric assay. (B), Effects of resveratrol 
and/or TRAIL on caspase-8 activity. LNCaP cells were treated with resveratrol (0–30 µM) in the presence or absence of TRAIL 
(50 nM) for 24 h. At the end of incubation period, caspase-8 activity was measured by flurometric assay. (C), Effects of resver-
atrol and/or TRAIL on cleavage of pro-caspase-8, pro-caspase-3, pro-caspase-9 and PARP. LNCaP cells were pretreated with 
resveratrol (0, 10 or 20 µM) for 24 h followed by treatment with or without TRAIL (50 nM) for 24 h. At the end of incubation 
period, cells were harvested, and the Western blot analysis was performed to measure the expression of pro-caspase-8, 
cleaved-caspase-3, cleaved-caspase-9 and PARP. β-actin was used as a loading control.Journal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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mitochondria to cytosol (appearance of red color mito-
chondria, and diffused green color of cyto c or Smac).
It has been shown that mitochondrial proteins such as
cytochrome c, AIF, Smac/DIABLO and Omi/Htr2 are
released into the cytosol in cells undergoing apoptosis
[51,52]. These proteins are involved in caspase-dependent
and -independent apoptosis. We next confirmed the
release of mitochondrial proteins in LNCaP cells treated
with resveratrol in the presence of absence of TRAIL by
Western blotting using cytoplasmic fraction (Fig. 6B and
6C). Treatment of LNCaP cells with resveratrol caused the
release of cytochrome c, AIF, Smac/DIABLO and Omi/
Htr2 from mitochondria to cytosol in a time-dependent
manner. TRAIL had no effect on the release of mitochon-
drial proteins. The combination of resveratrol and TRAIL
enhanced the release of cytochrome c, AIF and Omi from
mitochondria to cytosol.
We next confirmed the involvement of Smac/DIABLO in
resveratrol-induced apoptosis by inhibition of Smac
expression (RNAi technology) or exogenous administra-
tion of Smac peptide (Fig. 6D and 6E). We have previ-
ously shown that Smac N7 peptide can sensitize resistant
cells to undergo apoptosis by TRAIL [28] or curcumin
[53]. The data revealed that plasmid expressing Smac
siRNA significantly inhibited resveratrol-induced apopto-
sis (Fig. 6D), and Smac N7 peptide significantly enhanced
apoptosis induced by resveratrol (Fig. 6E). These data sug-
gest that Smac is an important regulator of resveratrol-
induced apoptosis.
Resveratrol induces Bax and p53 translocation to 
mitochondria
The proapoptotic protein Bax is translocated to mitochon-
dria where it oligomerizes with Bak and causes the release
of mitochondrial proteins [28,54]. Furthermore, a new
role of p53, a transcriptional independent mechanism,
has recently been reported where it translocates to mito-
Effects of resveratrol on the expressions of Bcl-2 family members and IAPs Figure 4
Effects of resveratrol on the expressions of Bcl-2 family members and IAPs. (A and B), Effects of resveratrol on protein expres-
sion of Bcl-2 family members. Cells were treated with resveratrol (0–20 µM) for 24 or 48 h. The expressions of Noxa, Bim, 
Bak, Bax, Bid, PUMA, Bcl-2, and Bcl-XL were examined by Western blot analysis. Actin antibody was used as a loading control. 
BimEL = Bim extra large, BimL = Bim large, BimS = Bim short. (C), Effects of resveratrol on the expressions of IAPs. Cells were 
treated with resveratrol (0–20 µM) for 24 or 48 h. Crude proteins were subjected to SDS-PAGE and immunoblotted with 
antibody specific for XIAP, survivin, cIAP1 or cIAP2. β-actin antibody was used as a loading control.Journal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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chondria and interacts with the Bcl-2 family members to
regulate apoptosis. We therefore examined whether res-
veratrol induces translocation of Bax and p53 to mito-
chondria by immunohistochemistry (Fig. 7A) and
Western blotting of mitochondrial fractions (Fig. 7B). We
have used anti-Bax 6A7 antibody (BD Pharmingen) which
recognizes the conformationally altered Bax protein. In
control cells, Bax and p53 were not colocalized to mito-
chondria which was clear from distinct red (mitochon-
dria) and green (Bax or p53) color. Treatment of LNCaP
cells with resveratrol resulted in translocation of Bax and
p53 to mitochondria (appearance of yellow mitochon-
dria) at 2 and 4 h. We next confirmed the translocation of
Bax and p53 by Western blot analysis in isolated mito-
chondrial fraction (Fig. 7B). Treatment of LNCaP cells
with resveratrol resulted in translocation of Bax and p53
to mitochondria as early as 2 h and continued up to 8 h.
The Bax antibody recognizes three bands which could be
monomer, dimmer and tetramer of Bax. Interestingly,
translocation of Bax and p53 to the mitochondria (2 h)
preceded the drop in mitochondrial membrane potential
and cytochrome c release (6 h).
Death receptor pathway is involved in sensitization of 
TRAIL-resistant LNCaP cells by resveratrol
Since pretreatment of LNCaP cells with resveratrol sensi-
tizes TRAIL-resistant cells to undergo apoptosis, we sought
to examine the contribution of death receptor pathway by
using dominant negative FADD and caspase-8 siRNA. The
FADD is an adapter protein which links death receptors to
procaspases-8 in cells undergoing apoptosis [22]. In order
to examine the involvement of death receptor pathway,
we inhibited the expression of FADD or caspase-8. LNCaP
cells were transfected with plasmid expressing DN-FADD,
caspase-8 siRNA or respective controls (Fig. 8A). Data
revealed that DN-FADD and caspase-8 siRNA inhibited
the expression of FADD and caspase-8 proteins, respec-
tively. We next examined whether overexpression of DN-
FADD or caspase-8 siRNA inhibited the ability of resvera-
trol to sensitize cells to TRAIL (Fig. 8B and 8C). Resvera-
trol induced apoptosis in a dose-dependent manner,
whereas TRAIL had no effect. Pretreatment of LNCaP cells
with resveratrol sensitized cells to undergo apoptosis by
TRAIL. As expected, DN-FADD or caspase-8 siRNA inhib-
ited the ability of resveratrol to sensitize LNCaP cells to
Effects of resveratrol and/or TRAIL on mitochondrial membrane potential (∆ψm) Figure 5
Effects of resveratrol and/or TRAIL on mitochondrial membrane potential (∆ψm). (A), Resveratrol induces drop in ∆ψm. 
LNCaP cells were treated with or without resveratrol (20 µM) for 0–24 h. Cells were stained with JC1 dye, and ∆ψm was 
measured by a fluorometer as per manufacturer's instructions. (B), Interactive effects of resveratrol and TRAIL on ∆ψm. 
LNCaP cells were treated with resveratrol (20 µM) in the presence or absence of TRAIL (50 nM) for 1, 2, 8 and 16 h. Cells 
were stained with JC1 dye, and ∆ψm was measured.Journal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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Effects of resveratrol and/or TRAIL on mitochondrial dysfunction Figure 6
Effects of resveratrol and/or TRAIL on mitochondrial dysfunction. (A), Resveratrol induces the release of cytochrome c and 
Smac/DIABLO from mitochondria to cytosol. LNCaP cells were treated with or without resveratrol (20 µM) for 12 or 24 h. 
Cells were fixed, permeabilized and stained with anti-cytochrome c or anti-Smac/DIABLO antibody at 4°C for 18 h. After 
washing, cells were stained with mitotracker red (mitochondrial staining), DAPI (nuclear staining) and secondary antibody con-
jugated with FITC (for cyto c or Smac). Red color = mitochondria, green color = cytochrome c or Smac/DIABLO, blue color 
= nucleus, yellow = co-locolization of cyto c and Smac/DIABLO to mitochondria. (B), Resveratrol releases mitochondrial pro-
teins. LNCaP cells were treated with resveratrol (20 µM) for 0, 6, 12, or 24 h, and cytoplasmic fractions were prepared. Crude 
proteins were subjected to SDS-PAGE and immunoblotted with anti-cytochrome c (Cyto C), anti-AIF, anti-Smac/DIABLO or 
anti-Omi antibody. β-Actin was used as a loading control. (C), Interactive effects of resveratrol and TRAIL on the release of 
mitochondrial proteins. LNCaP cells were treated with resveratrol (20 µM) in the presence or absence of TRAIL (50 nM) for 
12 h, and cytoplasmic fractions were prepared. Crude proteins were subjected to SDS-PAGE and immunoblotted with anti-
Cyto C, anti-AIF, anti-Smac/DIABLO or anti-Omi antibody. β-Actin was used as a loading control. (D), Effects of Smac siRNA 
on resveratrol-induced apoptosis. Western blotting data demonstrate that transient transfection of LNCaP cells with Smac 
siRNA plasmid inhibited Smac protein expression at 48 h. LNCaP cells were transiently transfected with either control plasmid 
or plasmid expressing Smac siRNA along with plasmid (pCMV-LacZ) encoding the β-galactosidase (β-Gal) enzyme. There was 
no difference in transfection efficiency between groups. Cells were treated with various doses of resveratrol (0–30 µM) for 48 
h, and apoptosis was measured. (E), Enhancement of resveratrol-induced apoptosis by Smac N-7 peptide. LNCaP cells were 
pretreated with either 25 µM control Smac peptide or Smac N7 peptide for 4 h, and treated with various doses of resveratrol 
(10, 20 or 30 µM) for 48 h. Apoptosis was measured by TUNEL assay. Data represent mean ± SD. * = significantly different 
from respective control (P < 0.05).Journal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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TRAIL. We also confirmed the role of caspase-8 by using
the caspase-8 inhibitor z-IETD-fmk. Caspase-8 inhibitor
also inhibited the ability of resveratrol to sensitize TRAIL-
resistant cells (Fig. 8D). These data suggest the involve-
ment of death receptor pathway in sensitization of TRAIL-
resistant cells by resveratrol.
Sensitization of TRAIL-resistant LNCaP cells by resveratrol 
involves ROS production
Recent studies have shown that cancer preventive agent
induced apoptosis through generation of ROS. Genera-
tion of reactive oxygen species by oxidative damage play
an important role in cells undergoing apoptosis [30,55].
The treatment of LNCaP cells with resveratrol resulted in
ROS production with a maximum at 150 min, after that it
slightly declined (Fig. 9A). We next examined whether,
resveratrol causes oxidative stress that is responsible for
caspase-3 activation and apoptosis. Pretreatment of
LNCaP cells with 50 mM N-acetylcysteine (NAC) fol-
lowed by resveratrol (0–30 µM) resulted in a significant
inhibition of resveratrol-induced caspase-3 activity (Fig.
9B) and apoptosis (Fig. 9C). Taken together, our results
suggest that resveratrol-induced apoptosis is also medi-
ated through generation of ROS, which, in turn, may acti-
vate cell intrinsic pathway of apoptosis.
Since resveratrol sensitizes TRAIL-resistant LNCaP cells to
undergo apoptosis, we measured the involvement of ROS
in this process. As shown above, treatment of LNCaP cells
with resveratrol resulted in generation of ROS, activation
of caspase-3, and induction of apoptosis (Fig. 9D, E and
9F). TRAIL alone had no effect on ROS production,
although it induced caspase-3 activity and apoptosis. The
combination of resveratrol and TRAIL significantly pro-
duced more ROS than resveratrol alone (Fig. 9A). The pre-
treatment of LNCaP cells with NAC inhibited generation
of ROS by resveratrol alone, and resveratrol and TRAIL.
Similarly, the pretreatment of LNCaP cells with NAC
inhibited caspase-3 activity and apoptosis induced by res-
veratrol alone, and resveratrol and TRAIL. These data sug-
gest that generation of ROS is one of the mechanisms by
which resveratrol sensitizes TRAIL-resistant LNCaP cells.
Translocation of Bax and p53 to mitochondria Figure 7
Translocation of Bax and p53 to mitochondria. (A), Resveratrol induces translocation of Bax and p53 to the mitochondria. 
LNCaP cells were treated with or without resveratrol (20 µM) for 2 or 4 h. Cells were fixed, permeabilized and stained with 
anti-Bax antibody at 4°C for 18 h. After washing, cells were stained with mitotracker red (mitochondrial staining), DAPI 
(nuclear staining) and secondary antibody conjugated with FITC (for Bax). Red color = mitochondria, green color = Bax, blue 
color = nucleus, yellow = translocation of Bax or p53 to mitochondria. (B), Translocation of Bax and p53 to mitochondria. 
LNCaP cells were treated with resveratrol for 0, 2, 4 or 8 h. Mitochondrial fractions were prepared, subjected to SDS-PAGE, 
and immunoblotted with anti-Bax, anti-p53 or anti-COX IV antibody.Journal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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Discussion
Dietary supplements and complementary and alternative
medication (CAM) are becoming increasingly popular
among patients with cancer. Recently, there has been
major interest in development of compounds of natural
origin with chemopreventive and chemotherapeutic
properties. Resveratrol is one such compound that is
found in high concentrations in red wine and has a wide
range of promising pharmacological properties. In the
present study, we have shown that resveratrol not only
induced apoptosis but also sensitized TRAIL-resistant
human prostate cancer LNCaP cells through activation of
multiple signaling pathways. Resveratrol-induced apopto-
sis disrupted mitochondrial homeostasis which was evi-
dent by the drop in mitochondrial membrane potential
and release of mitochondrial proteins (cytochrome C,
Smac/DIABLO, AIF, and Omi/HtrA2). Resveratrol
induced expression of proapoptotic proteins (Bax, Bak,
PUMA, Noxa and Bim) and inhibited expression of antia-
poptotic proteins (Bcl-2 and Bcl-XL). These proteins exert
their effect mainly at the level of mitochondria. Further-
more, resveratrol generated ROS, translocated p53 and
Bax to mitochondria where these proteins may interact
with other Bcl-2 family members to cause permeabiliza-
tion of outer mitochondrial membrane and release of
mitochondrial proteins leading to caspase activation and
Involvement of death receptor pathway Figure 8
Involvement of death receptor pathway. (A), Expression of FADD and caspase-8 by Western blot analysis. LNCaP cells were 
transiently transfected with either control plasmid or plasmid expressing dominant negative FADD (DN-FADD) or caspase-8 
siRNA along with plasmid (pCMV-LacZ) encoding β-galactosidase (β-Gal) enzyme. There was no difference in transfection effi-
ciency among groups. Cell lysates were run on SDS-PAGE to measure the expression of FADD and caspase-8 by Western blot 
analysis. (B), Effects of dominant negative FADD on resveratrol and/or TRAIL-induced apoptosis. LNCaP cells were transiently 
transfected as described above. Cells were treated with resveratrol (0, 10 or 20 µM) in the presence or absence of TRAIL (50 
nM) for 48 h, and apoptosis was measured. Data represent mean ± SD. * = Significantly different from respective control; # and 
$ = treatment groups were significantly different, P < 0.05. (C), Effects of caspase-8 siRNA on resveratrol and/or TRAIL-
induced apoptosis. LNCaP cells were transiently transfected as described above. Cells were treated with resveratrol (0, 10 or 
20 µM) in the presence or absence of TRAIL (50 nM) for 48 h. Apoptosis was measured by DAPI staining. Data represent 
mean ± SD. * = Significantly different from respective control; # and $ = treatment groups were significantly different, P < 0.05. 
(D), Effects of caspase-8 inhibitors on resveratrol and/or TRAIL-induced apoptosis. LNCaP cells were pretreated with either 
control peptide or caspase-8 inhibitor z-IETD-fmk (50 µM) for 4 h, followed by treatment with resveratrol (0, 10 or 20 µM) in 
the presence or absence of TRAIL (50 nM) for 48 h. Apoptosis was measured by DAPI staining. Data represent mean ± SD. * 
= Significantly different from respective control; # and $ = treatment groups were significantly different, P < 0.05.Journal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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Involvement of reactive oxygen species in sensitization of TRAIL-resistant LNCaP cells by resveratrol Figure 9
Involvement of reactive oxygen species in sensitization of TRAIL-resistant LNCaP cells by resveratrol. (A), Generation of ROS 
by resveratrol. LNCaP cells were seeded in 96-well plates, loaded with 5 µM CM-H2DCFDA dye for 30 min, and treated with 
either resveratrol (20 µM) or N-acetylcysteine (NAC) (50 mM) plus resveratrol (20 µM) for 0–360 min. Fluorescence was 
measured by a fluorometer as per manufacturer's instructions (EMD Biosciences/Molecular Probes). * = significantly different 
from respective controls, P < 0.05. (B), Inhibition of resveratrol-induced caspase-3 activity by NAC. LNCaP cells were pre-
treated with 50 mM NAC for 2 h followed by treatment with resveratrol (10, 20 or 30 µM) for 12 h, and caspase-3 activity was 
measured by a fluorometer as per manufacturer's instructions. * = significantly different from respective control; %, # or $ = 
significantly different from each other, P < 0.05. (C), Inhibition of resveratrol-induced apoptosis by NAC. LNCaP cells were 
pretreated with 50 mM NAC for 2 h followed by treatment with resveratrol (10, 20 or 30 µM) for 48 h, and apoptosis was 
measured by TUNEL assay. a, c and e were significantly different from b, d and f, respectively, P < 0.05. (D), Interactive effects 
of resveratrol and TRAIL on ROS production. LNCaP cells were pretreated with NAC (50 mM) for 2 h followed by treatment 
with resveratrol (20 µM) with or without TRAIL (50 nM) for 120 min., and ROS production was measured. * = significantly dif-
ferent from respective controls, P < 0.05; # or % = significantly different between groups, P < 0.05. (E), Interactive effects of 
resveratrol and TRAIL on caspase-3 activity. LNCaP cells were pretreated with 50 mM NAC for 2 h followed by treatment 
with resveratrol (20 µM) for 12 h, and caspase-3 activity was measured. * = significantly different from respective controls, P < 
0.05; # or % = significantly different between groups, P < 0.05. (F), Interactive effects of resveratrol and TRAIL on apoptosis. 
LNCaP cells were pretreated with 50 mM NAC for 2 h followed by treatment with resveratrol (20 µM) with or without TRAIL 
(50 nM) for 48 h, and apoptosis was measured by TUNEL assay. * = significantly different from respective controls, P < 0.05; # 
= significantly different between groups, P < 0.05.Journal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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apoptosis. Finally, the ability of resveratrol to sensitize
TRAIL-resistant cells suggest that its can be used either
alone or in combination with TRAIL to prevent and/or
treat human prostate cancer.
Apoptosis can be initiated by extracellular and intracellu-
lar signals that trigger a complex machinery of pro-apop-
totic proteases and mitochondrial functions. It is
integration of multiple survival and death signals that
determine whether a cell is to survive or undergo apopto-
sis. We and others have shown that the Bcl-2 family mem-
bers are the mediators of cell survival and apoptosis
[31,32,45,51]. The inhibition of antiapoptotic Bcl-2 and
Bcl-XL, and induction of proapoptotic Bax, Bak, PUMA,
Noxa, Bim, and Bid proteins by resveratrol suggest that the
relative expression of these proteins can determine the
sensitivity of cancer cells to TRAIL. In a recent report, we
have shown that another chemopreventive agent curcu-
min inhibited the expression of antiapoptotic Bcl-2 and
Bcl-XL, and induced the expression of proapoptotic Bax,
Bak, PUMA, Noxa, and Bim in prostate cancer cells [53].
Similarly, resveratrol enhanced the apoptosis-inducing
potential of TRAIL in androgen-insensitive prostate cancer
PC-3 cells by regulating Bcl-2 family members [56].
In the present study, resveratrol induced the release of
mitochondrial Smac/DIABLO, cytochrome c, AIF and
Omi/HtrA2. Cytochrome c forms apoptosomes, in the
presence of ATP/dATP and Apaf-1, which activate caspase-
9 and subsequently effector caspases such as caspase-3
and caspase-7 leading to cell death [34]. Smac/DIABLO,
AIF and Omi do not require apoptosome formation for
apoptosis induction. In comparison, Smac/DIABLO binds
to IAPs (XIAP, survivin, c-IAP-1, or c-IAP-2) and abrogates
IAP-mediated inhibition of caspase-3 and caspase-7,
thereby facilitating caspase-mediated apoptosis. The pro-
and anti-apoptotic Bcl-2 family proteins regulate the
release of these mitochondrial proteins. Furthermore, our
data demonstrate that resveratrol inhibits the expression
of XIAP and survivin, suggesting the inhibition of IAPs
will allow more free caspases to bind their substrates and
finally induce apoptosis.
We have previously demonstrated that TRAIL induces
apoptosis in prostate cancer cells through the release of
cytochrome c and Smac/DIABLO [40,43], and Bax and
Bak differentially regulate the release of cytochrome c and
Smac/DIABLO from mitochondria to cytosol in MEFs
[28]. Here, we showed that TRAIL-resistant LNCaP cells
can be sensitized not only by resveratrol, but also by the
mature form of Smac/DIABLO which will bypass mito-
chondria. Our data clearly demonstrate the requirement
of Smac/DIABLO for sensitization of TRAIL-resistant
LNCaP cells. We have demonstrated that the down-regu-
lation of Smac by RNAi conferred resistance whereas addi-
tion of a Smac-mimetic peptide enhanced resveratrol-
induced apoptosis, suggesting that Smac release is
required for efficient resveratrol-induced apoptosis. To
our knowledge, this represents the first finding that regu-
lation of Smac release by resveratrol is an important event
for apoptosis induction. However, Smac RNAi could not
completely suppress resveratrol-induced apoptosis, sug-
gesting that there may be additional, Smac-independent,
mechanisms operating to induce apoptosis. In support of
this, our data suggest that other mitochondrial proteins
cytochrome c, AIF and Omi/HtrA2 may contribute cell
death process.
TP53 is the most frequently mutated and intensely stud-
ied tumor suppressor gene [57,58]. After DNA damage or
proto-oncogene activation, p53 is stabilized by post-trans-
lational modifications and exerts its anti-tumorigenic
activity by inducing cell cycle arrest or apoptosis [59,60].
Although most data suggest that p53 regulates its activities
through transcription activation, there is growing evi-
dence that p53 exerts pro-apoptotic activity in a transcrip-
tion-independent manner [61]. In response to
appropriate apoptotic signals, p53 translocates to mito-
chondria, where it interacts with Bak, Bcl-2 and Bcl-XL and
induces the release of mitochondrial proteins (e.g. cyto-
chrome c) by acting in a manner similar to the BH-3-only
pro-apoptotic proteins [62,63]. Caspase activation by p53
occurs through the release of apoptogenic factors from the
mitochondria, including cytochrome c and Smac/DIA-
BLO. Similarly, we have shown that curcumin induced
translocation of p53 to mitochondria and disrupted mito-
chondrial homeostasis in prostate cancer cells [53]. In the
present study, resveratrol induced translocation of p53 to
mitochondria as early as 2 h, and the time of translocation
of p53 was similar to that of proapoptotic protein Bax.
Reactive oxygen species (ROS) include oxygen ions, free
radicals and peroxides both inorganic and organic. They
are generally very small molecules and are highly reactive
due to the presence of unpaired valence shell electrons.
ROS are formed as natural byproduct of the normal
metabolism of oxygen and have important roles in cell
signaling [64]. However, during times of environmental
stress ROS levels can increase dramatically, which can
result in significant damage to cell structures. This cumu-
lates into a situation known as oxidative stress. Cells are
normally able to defend themselves against ROS damage
through the use of enzymes such as superoxide dis-
mutases and catalases. Small molecule antioxidants such
as ascorbic acid (vitamin-C), uric acid, and glutathione
also play important roles as cellular antioxidants. Simi-
larly, polyphenol antioxidants assist in preventing ROS
damage by scavenging free radicals. At low levels, ROS
such as superoxide, hydrogen peroxide, and hydroxyl rad-
ical, may function in cell signaling processes, whereas atJournal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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higher levels, ROS may damage cellular macromolecules
(such as DNA and RNA) and participate in apoptosis
[64,65]. ROS have been implicated as a key factor in the
activation of p53 by many chemotherapeutic drugs. ROS-
mediated disruption of ∆ψm constitutes a pivotal step in
the apoptotic pathway of p53. Apoptosis triggered by p53
has been reported to be dependent on an increase in ROS
and the release of apoptotic factors from mitochondrial
damage [66,67]. These studies suggest that ROS are down-
stream mediators in p53-dependent apoptosis in tran-
scription-dependent or transcription-independent
pathways. When cells are exposed to oxidative stress, p53
is expressed at high levels by posttranslational modifica-
tions, including phosphorylation, acetylation, and glyco-
sylation [68,69]. These events occur rapidly and lead to
the activation of p53, resulting in either cell cycle arrest or
apoptosis. These findings suggest the novel functions of
ROS as p53 activators or p53 downstream effectors.
Studies outlined in this paper are highly significant
because identification of a non-toxic dietary agent resver-
atrol that can delay onset and/or progression of prostate
cancer could, in the long term, have a profound impact on
the overall incidence of this malignancy. The capacity of
resveratrol to promote killing of prostate tumor cells in
response to TRAIL through induction of death receptors
and activation of caspases in otherwise apoptosis-resistant
cells suggests that resveratrol may induce fundamental
alterations in cell signaling pathways leading to apoptosis.
Conclusion
We have demonstrated that resveratrol induces apoptosis
in prostate cancer cells through multiple mechanisms. It
generates ROS, translocates p53 and Bax to mitochondria,
regulates Bcl-2 family members and IAPs, and causes the
release of mitochondrial proteins. Furthermore, our study
establishes a direct role of p53 on the caspase-dependent
mitochondrial death pathway and suggests that p53 inter-
acts at the level of the mitochondria to influence resvera-
trol sensitivity. Gene therapy approach to deliver Smac/
DIABLO can also be undertaken to sensitize TRAIL-resist-
ant LNCaP cells. The ability of resveratrol to sensitize
TRAIL-resistant LNCaP cells suggest that it can be com-
bined with TRAIL for the prevention and/or treatment of
prostate cancer.
Methods
Reagents
Anti-cytochrome c, anti-p53, and anti-Smac/DIABLO
antibodies were purchased from BD Biosciences/
Pharmingen (San Diego, CA). JC-1, and 5-(and-6)-chlo-
romethyl-2',7'-dichlorodihydrofluorescein diacetate,
acetyl ester (CM-H2DCFDA) were purchased from Invitro-
gen/Molecular Probes, Inc. (Eugene, OR). Antibodies
against Bcl-2, Bcl-XL, Bax, Bak, PUMA, Noxa, Bim, Bid,
AIF, survivin, XIAP, cIAP1, cIAP2 and β-actin were pur-
chased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Caspase-8 siRNA, Bax siRNA and control plasmids
were purchased from BioVision, Inc. (Mountain View,
CA). Enhanced chemiluminescence (ECL) Western blot
detection reagents were from Amersham Life Sciences Inc.
(Arlington Heights, IL). Smac siRNA and control plasmids
were purchased from Imgenex (San Diego, CA). N-acetyl-
cysteine (NAC), Terminal Deoxynucleotidyl Transferase
Biotin-dUTP Nick End Labeling (TUNEL) assay kit, and
caspase-3 and caspase-8 activity kits were purchased from
EMD Biosciences/Calbiochem (San Diego, CA). Resvera-
trol was purchased from LKT Laboratories, Inc. (St. Paul,
MN). Smac-N7 peptide (H-AVPIAQK-P-RQIKIW-
FQNRRMKWKK-OH) and control peptide (H-MKSDFYF-
P-RQIKIWFQNRRMKWKK-OH) were modified to be cell
permeable by linking the lysine carboxyl terminal to the
arginine of Antennapedia homeodomain 16-mer peptide
(underlined) via a proline linker. TRAIL was produced
according to published procedures [38].
Cell Culture
LNCaP cells were obtained from the American Type Cul-
ture Collection (Manassas, VA) and cultured in RPMI
1640 supplemented with 10% fetal bovine serum (FBS)
and 1% antibiotic-antimycotic (Invitrogen) at 37°C in a
humidified atmosphere of 95% air and 5% CO2. Normal
human prostate epithelial cells (PrECs) were purchased
from Clonetics/Bio Whittaker (Walkersville, MD), and
cultured in PrEBM medium (Cambrex, Rockland, ME).
XTT Assay
Cells (1 × 104 in 200 µl culture medium per well) were
seeded in 96-well plate and treated with or without drugs
and incubated for various time points at 37°C and 5%
CO2. Before the end of the experiment, 50 µl XTT labeling
mixture (final concentration, 125 µM XTT (sodium 2,3-
Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide inner salt) and 25 µM PMS (phenazine
methosulphate) per well was added and plates were incu-
bated for further 4 h at 37°C and 5% CO2. The spectro-
photometric absorbance of the sample was measured
using a microtitre plate reader. The wavelength to measure
absorbance of the formazon product was 450 nm, and the
reference wavelength was 650 nm.
Plasmids expressing dominant negative FADD and short 
hairpin RNA
Cells were plated in 60-mm dishes in RPMI 1640 contain-
ing 10% FBS and 1% penicillin-streptomycin mixture at a
density of 1 × 106 cells/dish. The next day transfection
mixtures were prepared. Cells were transfected with
expression constructs encoding dominant negative FADD
(DN-FADD) or empty vector in the presence of an expres-
sion vector pCMV-LacZ (Invitrogen life technologies)Journal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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expressing β-galactosidase. For each transfection, 2 µg of
DNA was diluted into 50 µl of medium without serum.
After the addition of 3 µl of LipofectAMINE (Invitrogen
life technologies) into 50 µl Opti-MEM medium, the
transfection mixture was incubated for 10 min at room
temperature. Cells were washed with serum-free medium,
the transfection mixture was added, and cultures were
incubated for 24 hrs in the incubator. The next day, cul-
ture medium was replaced with fresh RPMI 1640 contain-
ing 10% FBS and 1% penicillin-streptomycin mixture.
Cells were treated with or without resveratrol. At the end
of incubation, cells were harvested to measure protein
expression by western blot analysis or apoptosis by DAPI
staining.
For siRNA experiment, cells were transiently transfected
with plasmids expressing caspase-8 siRNA (pGB-Caspase-
8), Bax siRNA (pGB-Bax siRNA) or control siRNA (pGB-
control) in the presence of pCMV-LacZ (Invitrogen life
technologies) vector expressing β-galactosidase to control
transfection efficiency. Cells were treated as described
above.
Soft Agar Assay
LNCaP cells (2 × 104 cells/well) were seeded in 12-well
culture dishes in RPMI/0.35% bacto-agar over a bottom
layer of RPMI/0.6% bacto-agar. Cells were then fed with
growth media (100–200 µl/well) once a week until colo-
nies grew to a suitable size for observation (about 3
weeks). Number of colonies were counted after they were
stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (1 mg/ml, 100 µl/well) overnight
for better visualization.
Apoptosis
Apoptosis was measured by the terminal deoxynucleoti-
dyl transferase-mediated nick end-labeling method,
which examines DNA strand breaks during apoptosis.
Briefly, 1 × 105 cells were treated with curcumin at the
indicated doses for various time points at 37°C. Thereaf-
ter, cells were washed with PBS, air-dried, fixed with 4%
paraformaldehyde, and then permeabilized with 0.1%
Triton ×-100 in 0.1% sodium citrate. After washing, cells
were incubated with reaction mixture for 60 minutes at
37°C. Stained cells were mounted and analyzed under a
fluorescence Olympus microscope (Olympus America
Inc, Melville, NY). Pictures were captured using a Photo-
metrics Coolsnap CF color camera (Olympus) and SPOT
software (Diagnostic Instruments Inc., Sterling Heights,
MI). Data were confirmed by staining cells with DAPI as
previously described [41].
Caspase Assay
Cells (3 × 104 per well) were seeded in a 96-well plate with
200 µl culture medium. Approximately 16 h later, cells
were treated with various doses of resveratrol to induce
apoptosis. Casapse-3 and caspase-8 activities were meas-
ured as per manufacturer's instructions (EMD Bio-
sciences) with a fluorometer.
Cellular Fractionation
Purified mitochondrial preparations were made as we
described elsewhere [28]. In brief, cell pellets were resus-
pended in ice-cold buffer A (250 mM sucrose, 20 mM
HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 17 µg/ml phenylmethylsulfonyl fluo-
ride, 8 µg/ml aprotinin, 2 µg/ml leupeptin, pH 7.4]. Cells
were homogenize with either 20 strokes of a Dounce
homogenizer or 23-gauge needles on ice, and the suspen-
sion was centrifuged at 750 × g for 10 min at 4°C to
remove nuclei. The supernatant was spun and the result-
ing mitochondrial pellets were layered over a 1 to 2 mM
sucrose step gradient [10 mM Tris (pH 7.6), 5 mM EDTA,
2 mM DTT, and 1 × protease inhibitor cocktail) and cen-
trifuged at 22,000 × g for 30 min at 4°C. Mitochondria
were collected at the 1 to 1.5 M interphase. The superna-
tant from the previous step was spun to obtain the cyto-
plasmic S100 fraction. The protein concentrations were
determined by Bradford method (Bio-Rad, Hercules, CA).
The purification of S-100 protein was determined by
Western blot analysis using anti-cytochrome oxidase IV
antibody.
Western Blot Analysis
Cell pellets were lysed in RIPA buffer containing 1 × pro-
tease inhibitor cocktail, and protein concentrations were
determined using the Bradford assay (Bio-Rad, Philadel-
phia, PA). Cell lysates were electrophoresed in 12.5% SDS
polyacrylamide gels and then transferred onto nitrocellu-
lose membranes. After blotting in 5% nonfat dry milk in
TBS, the membranes were incubated with primary anti-
bodies at 1:1,000 dilution in TBS-Tween 20 overnight at
4°C, and then secondary antibodies conjugated with
horseradish peroxidase at 1:5,000 dilution in TBS-Tween
20 for 1 hour at room temperature. Protein bands were
visualized on X-ray film using an enhanced chemilumi-
nescence system.
Measurement of Mitochondrial Membrane Potential 
(∆Ψm)
Mitochondrial membrane potential was measured as we
described elsewhere [28]. Mitochondrial energization was
determined by retention of JC-1 dye (Molecular Probes
Inc., Eugene) as we described earlier [28,40]. Briefly, drug
treated cells (5 × 105) were loaded with JC-1 dye (1 µg/ml)
during the last 30 min of incubation at 37 °C in a 5% CO2
incubator. Cells were washed in PBS twice. Fluorescence
was monitored in a fluorometer using 570-nm excitation/
595-nm emission for the J-aggregate of JC1 [70]. ∆Ψm was
calculated as a ratio of the fluorescence of J-aggregateJournal of Molecular Signaling 2007, 2:7 http://www.jmolecularsignaling.com/content/2/1/7
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(aqueous phase) and monomer (membrane-bound)
forms of JC1.
Determination of Reactive Oxygen Species (ROS)
ROS was measured as we described elsewhere [53]. In
brief, LNCaP cells were seeded in 96-well plates. After 16
h, cells were loaded with 5 µM CM-H2DCFDA dye for 30
min, and treated with either curcumin (10 or 20 µM) or
0.05% DMSO for 0–360 min. Fluorescence was measured
at excitation wavelength of 488 nm and emission wave-
length of 515 nm using a fluorescence plate reader.
Immunocytochemistry
Cells were grown on fibronectin-coated coverslips (Beck-
ton Dickinson, Bedford, MA), washed in PBS, and fixed
for 15 min in 4% paraformaldehyde. Cells were permea-
bilized in 0.1% Triton ×-100, washed and blocked in 10%
normal goat serum. Cells were incubated with anti-cyto-
chrome c, anti-Smac, anti-Bax or anti-p53 antibody
(1:200) for 18 h at 4°C. Cells were then washed and incu-
bated with fluorescently labeled secondary antibodies
(1:200) along with DAPI (1 µg/ml) and mitotracker red
for 1 h at room temperature. Cells were washed and cov-
erslips were mounted using Vectashield (Vector Laborato-
ries, Burlington, CA). Isotype-specific negative controls
were included with each staining. Stained cells were
mounted and visualized under a fluorescence Olympus
microscope (Olympus America Inc.). Pictures were cap-
tured using a Photometrics Coolsnap CF color camera
(Olympus) and SPOT software (Diagnostic Instruments
Inc.).
Statistical Analysis
All data were presented as mean ± SD from at least three
sets of independent experiments. ANOVA analysis with
Turkey's multiple comparisons was used to determine the
significance of statistical differences between data at the
level of P < 0.05.
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